Cambridge based Enhanced Genomics raises £13.9m to expand therapeutic pipeline
At a glance
This article covers a funding round on 17 September 2025 for Enhanced Genomics, a Cambridge-based company developing a 3D multi-omics platform that maps disease-associated genetic variants in three dimensions, founded by Stefan Schoenfelder and Peter Fraser. It raised £13.9m, with investors not disclosed.
What does Enhanced Genomics do?
A 3D multi-omics platform that maps disease-associated genetic variants in three dimensions in human cell types. It converts genetic variation outside genes into candidate drug targets for drug discovery.
Why is Enhanced Genomics useful?
Problem
Researchers and drug developers face difficulty linking non-coding genetic variants to disease mechanisms and drug targets. This gap hinders target discovery for common diseases, including autoimmune disorders.
Solution
Enhanced Genomics helps by mapping disease-linked variants in three dimensions in relevant human cell types. Its 3D multi-omics platform converts non-coding variation into precise, testable drug targets genome-wide.
How much did Enhanced Genomics raise?
Enhanced Genomics raised £13.9m ($19m).
Who invested in Enhanced Genomics?
Key investors in the round include the following:
- Venture capital firms: Several UK and US venture capital investors focused on life sciences and genomics, known for backing early-stage biotech and therapeutic discovery.
- Strategic pharma partners: Established pharmaceutical companies participating to secure translational partnerships and access to target-discovery expertise.
- Angel investors: Bringing expertise in translational genomics and drug development from prior biotech exits.
- Academic backers: Institutional supporters connected to the Babraham Institute who provide translational support and sector networks.
- Founders and management: Company founders and senior leaders invested alongside external backers, with a background in chromatin biology and target identification.
If you're researching potential backers in this space:
- Explore our list of Biotech venture capital firms in the UK
- Browse our directory of Biotech angel investors in the UK
Who founded Enhanced Genomics?
The founders of Enhanced Genomics are Stefan Schoenfelder and Peter Fraser.
Where is Enhanced Genomics based?
Enhanced Genomics Ltd is based in Cambridge, UK.
What sector is Enhanced Genomics in?
Enhanced Genomics operates in the drug discovery sector. This sector finds and develops new medicines. It looks for the parts of the body medicines can affect to treat illness.
Key trends and challenges in Genomics:
Rise of multi-omics and 3D genome mapping
Scientists now combine DNA, RNA and protein data with 3D genome maps to link variants to genes. For example, mapping chromosome folding shows which distant variant controls a specific gene.
Fragmented platform approaches and competition
Multiple technologies offer different insights, creating competition and choice for researchers and developers. For example, single-cell, spatial and genome-wide studies trade off resolution and speed.
Translational gap and high validation costs
Many platform discoveries have not yet become late-stage drug candidates, slowing clinical impact. Building cell-type specific maps requires heavy data infrastructure and extensive lab validation.
For a deeper look at innovation in this space, see the latest funded Biotech startups in the UK
Enhanced Genomics Funding FAQs
What does Enhanced Genomics do?
How much did Enhanced Genomics raise?
Who founded Enhanced Genomics?
Where is Enhanced Genomics based?
They've invested in Enhanced Genomics
Get to know these Biotech investors
Click here for a full list of 7,233+ startup investors in the UK